N-(1,2,3,4-tetrahydro-2-naphthyl)glycine | 80871-73-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: N-(1,2,3,4-tetrahydro-2-naphthyl)glycine
• 英文别名: 2-(1,2,3,4-Tetrahydronaphthalen-2-ylamino)acetic acid
• CAS: 80871-73-4
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: RCZFVOPYHMJCST-UHFFFAOYSA-N

物化性质

• 沸点：
  387.0±42.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(1,2,3,4-tetrahydro-2-naphthyl)glycine 生成 N-(3-acetylthio-2-methylpropionyl)-N-(1,2,3,4-tetrahydro-2-naphthyl)glycine
  参考文献：
  名称：

  Chromanyl glycines

  摘要：

  新的双环化合物，包括其盐，其化学式如下：##STR1## 其中R.sup.1和R.sup.2，可以相同也可以不同，分别代表氢、卤素、低烷基、羟基、低烷氧基或芳基氧基，或者R.sup.1和R.sup.2共同代表低烷二氧基；R.sup.3和R.sup.4分别代表氢或低烷基；R.sup.5代表氢、低烷基或--CH.sub.2SR.sup.7（R.sup.7代表氢或酰基）；R.sup.6代表氢或酰基，或者R.sup.6和R.sup.7共同代表一个单键；X代表--CH.sub.2--、--O--或>N--R.sup.8（R.sup.8代表氢、酰基或低烷基）；n代表2、3或4，具有抑制肾素-血管紧缩素转化酶和激肽降解酶的活性，并可用作降压药物。

  公开号：

  US04521607A1
• 作为产物：
  描述：

  β-四氢萘酮 、 聚甘氨酸 生成 N-(1,2,3,4-tetrahydro-2-naphthyl)glycine
  参考文献：
  名称：

  Synthesis and pharmacology of some 2-aminotetralins. Dopamine receptor agonists

  摘要：

  A series of 2-amino-1,2,3,4-tetrahydronaphthalene compounds bearing substituents on the nitrogen and in the aromatic ring was synthesized from beta-tetralone intermediates. Compounds were screened in vivo for dopaminergic activity using tests in which apomorphine was especially active. It was found that apparent dopaminergic activity is inherent in 2-dialkylaminotetralins, the dipropylamine substitution being the most consistently productive amine group studies. Activity was greatly enhanced by proper substitution in the aromatic ring. The 5,6-dihydroxy group was the best potentiating group found. These data support the idea that the extended conformation for the phenylethylamine moiety of ampmorphine and dopamine is favorable for dopaminergic agonist activity. They also suggest that an unetherified catechol group may not be essential for such activity.

  DOI：

  10.1021/jm00238a008

文献信息

• Bicyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0035868A1

  公开（公告）日：1981-09-16

  New bicyclic compounds, inclusive of salts thereof, of the formula: wherein R1 and R2, which may be the same or different, each represent hydrogen, halogen, lower alkyl, hydroxyl, lower alkyloxy or aralkyloxy, or R' and R2 jointly represent lower alkylenedioxy: R3 and R4 each represent hydrogen or lower alkyl; R3 represents hydrogen,lower alkyl or -CH2SR7(R7 represents hydrogen or acyl): R6 represents hydrogen or acyl, or R6 and R7 jointly represent a single bond; X represents -CH2-, -O- orN-R5 (R8 represents hydrogen, acyl or lower alkyl); I and n represents 2, 3 or 4, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

  式中的新双环化合物，包括其盐类： 其中 R1 和 R2（可以相同或不同）各自代表氢、卤素、低级烷基、羟基、低级烷氧基或芳氧基，或 R' 和 R2 共同代表低级亚烷基二氧基：R3 和 R4 各自代表氢或低级烷基；R3 代表氢、低级烷基或-CH2SR7（R7 代表氢或酰基）：R6代表氢或酰基，或R6和R7共同代表单键；X代表-CH2-、-O-或N-R5（R8代表氢、酰基或低级烷基）；I和n代表2、3或4，具有抑制血管紧张素转换酶和缓激肽分解酶的活性，可用作降压药。
• OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS
  申请人：Almirall S.A.

  公开号：EP2387571A1

  公开（公告）日：2011-11-23
• US4521607A
  申请人：——

  公开号：US4521607A

  公开（公告）日：1985-06-04
• [EN] OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS D'OXADIAZOLE COMME AGONISTES DU RÉCEPTEUR S1P1
  申请人：ALMIRALL SA

  公开号：WO2010081692A1

  公开（公告）日：2010-07-22

  New compounds having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof wherein A is selected from the group consisting of -N-, -O- and -S-; B and C independently are selected from the group consisting of -N- and -O-, with the proviso that at least two of A, B and C are nitrogen atoms; G1 is selected from the group consisting of nitrogen atoms and -CRc- groups, wherein Rc represents a hydrogen atom, a halogen atom, a C1-4 alkyl group or a C1-4 alkoxy group.
• Chromanyl glycines
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04521607A1

  公开（公告）日：1985-06-04

  New bicyclic compounds, inclusive of salts thereof, of the formula: ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represent hydrogen, halogen, lower alkyl, hydroxyl, lower alkyloxy or aralkyloxy, or R.sup.1 and R.sup.2 jointly represent lower alkylenedioxy; R.sup.3 and R.sup.4 each represent hydrogen or lower alkyl; R.sup.5 represents hydrogen, lower alkyl or --CH.sub.2 SR.sup.7 (R.sup.7 represents hydrogen or acyl); R.sup.6 represents hydrogen or acyl, or R.sup.6 and R.sup.7 jointly represent a single bond; X represents --CH.sub.2 --, --O-- or >N--R.sup.8 (R.sup.8 represents hydrogen, acyl or lower alkyl); and n represents 2, 3 or 4, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

  新的双环化合物，包括其盐，其化学式如下：##STR1## 其中R.sup.1和R.sup.2，可以相同也可以不同，分别代表氢、卤素、低烷基、羟基、低烷氧基或芳基氧基，或者R.sup.1和R.sup.2共同代表低烷二氧基；R.sup.3和R.sup.4分别代表氢或低烷基；R.sup.5代表氢、低烷基或--CH.sub.2SR.sup.7（R.sup.7代表氢或酰基）；R.sup.6代表氢或酰基，或者R.sup.6和R.sup.7共同代表一个单键；X代表--CH.sub.2--、--O--或>N--R.sup.8（R.sup.8代表氢、酰基或低烷基）；n代表2、3或4，具有抑制肾素-血管紧缩素转化酶和激肽降解酶的活性，并可用作降压药物。